- IBDEI00P ; ; 01-AUG-2022
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,1136,1,3,0)
- ;;=3^Chronic myeloid leuk, BCR/ABL-positive, not achieve remis
- ;;^UTILITY(U,$J,358.3,1136,1,4,0)
- ;;=4^C92.10
- ;;^UTILITY(U,$J,358.3,1136,2)
- ;;=^5001792
- ;;^UTILITY(U,$J,358.3,1137,0)
- ;;=C92.11^^10^77^29
- ;;^UTILITY(U,$J,358.3,1137,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1137,1,3,0)
- ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in remission
- ;;^UTILITY(U,$J,358.3,1137,1,4,0)
- ;;=4^C92.11
- ;;^UTILITY(U,$J,358.3,1137,2)
- ;;=^5001793
- ;;^UTILITY(U,$J,358.3,1138,0)
- ;;=C92.12^^10^77^30
- ;;^UTILITY(U,$J,358.3,1138,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1138,1,3,0)
- ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in relapse
- ;;^UTILITY(U,$J,358.3,1138,1,4,0)
- ;;=4^C92.12
- ;;^UTILITY(U,$J,358.3,1138,2)
- ;;=^5001794
- ;;^UTILITY(U,$J,358.3,1139,0)
- ;;=C92.20^^10^77^22
- ;;^UTILITY(U,$J,358.3,1139,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1139,1,3,0)
- ;;=3^Atyp chronic myeloid leuk, BCR/ABL-neg, not achieve remis
- ;;^UTILITY(U,$J,358.3,1139,1,4,0)
- ;;=4^C92.20
- ;;^UTILITY(U,$J,358.3,1139,2)
- ;;=^5001795
- ;;^UTILITY(U,$J,358.3,1140,0)
- ;;=C92.21^^10^77^23
- ;;^UTILITY(U,$J,358.3,1140,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1140,1,3,0)
- ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
- ;;^UTILITY(U,$J,358.3,1140,1,4,0)
- ;;=4^C92.21
- ;;^UTILITY(U,$J,358.3,1140,2)
- ;;=^5001796
- ;;^UTILITY(U,$J,358.3,1141,0)
- ;;=C92.22^^10^77^24
- ;;^UTILITY(U,$J,358.3,1141,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1141,1,3,0)
- ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
- ;;^UTILITY(U,$J,358.3,1141,1,4,0)
- ;;=4^C92.22
- ;;^UTILITY(U,$J,358.3,1141,2)
- ;;=^5001797
- ;;^UTILITY(U,$J,358.3,1142,0)
- ;;=C92.30^^10^77^57
- ;;^UTILITY(U,$J,358.3,1142,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1142,1,3,0)
- ;;=3^Myeloid sarcoma, not having achieved remission
- ;;^UTILITY(U,$J,358.3,1142,1,4,0)
- ;;=4^C92.30
- ;;^UTILITY(U,$J,358.3,1142,2)
- ;;=^5001798
- ;;^UTILITY(U,$J,358.3,1143,0)
- ;;=C92.31^^10^77^56
- ;;^UTILITY(U,$J,358.3,1143,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1143,1,3,0)
- ;;=3^Myeloid sarcoma, in remission
- ;;^UTILITY(U,$J,358.3,1143,1,4,0)
- ;;=4^C92.31
- ;;^UTILITY(U,$J,358.3,1143,2)
- ;;=^5001799
- ;;^UTILITY(U,$J,358.3,1144,0)
- ;;=C92.32^^10^77^55
- ;;^UTILITY(U,$J,358.3,1144,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1144,1,3,0)
- ;;=3^Myeloid sarcoma, in relapse
- ;;^UTILITY(U,$J,358.3,1144,1,4,0)
- ;;=4^C92.32
- ;;^UTILITY(U,$J,358.3,1144,2)
- ;;=^5001800
- ;;^UTILITY(U,$J,358.3,1145,0)
- ;;=C92.90^^10^77^54
- ;;^UTILITY(U,$J,358.3,1145,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1145,1,3,0)
- ;;=3^Myeloid leukemia, unspecified, not having achieved remission
- ;;^UTILITY(U,$J,358.3,1145,1,4,0)
- ;;=4^C92.90
- ;;^UTILITY(U,$J,358.3,1145,2)
- ;;=^5001810
- ;;^UTILITY(U,$J,358.3,1146,0)
- ;;=C92.91^^10^77^53
- ;;^UTILITY(U,$J,358.3,1146,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1146,1,3,0)
- ;;=3^Myeloid leukemia, unspecified in remission
- ;;^UTILITY(U,$J,358.3,1146,1,4,0)
- ;;=4^C92.91
- ;;^UTILITY(U,$J,358.3,1146,2)
- ;;=^5001811
- ;;^UTILITY(U,$J,358.3,1147,0)
- ;;=C92.92^^10^77^52
- ;;^UTILITY(U,$J,358.3,1147,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1147,1,3,0)
- ;;=3^Myeloid leukemia, unspecified in relapse
- ;;^UTILITY(U,$J,358.3,1147,1,4,0)
- ;;=4^C92.92
- ;;^UTILITY(U,$J,358.3,1147,2)
- ;;=^5001812
- ;;^UTILITY(U,$J,358.3,1148,0)
- ;;=C93.00^^10^77^12
- ;;^UTILITY(U,$J,358.3,1148,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1148,1,3,0)
- ;;=3^Acute monoblastic/monocytic leukemia, not achieve remission
- ;;^UTILITY(U,$J,358.3,1148,1,4,0)
- ;;=4^C93.00
- ;;^UTILITY(U,$J,358.3,1148,2)
- ;;=^5001819
- ;;^UTILITY(U,$J,358.3,1149,0)
- ;;=C93.01^^10^77^10
- ;;^UTILITY(U,$J,358.3,1149,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1149,1,3,0)
- ;;=3^Acute monoblastic/monocytic leukemia, in remission
- ;;^UTILITY(U,$J,358.3,1149,1,4,0)
- ;;=4^C93.01
- ;;^UTILITY(U,$J,358.3,1149,2)
- ;;=^5001820
- ;;^UTILITY(U,$J,358.3,1150,0)
- ;;=C93.02^^10^77^11
- ;;^UTILITY(U,$J,358.3,1150,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1150,1,3,0)
- ;;=3^Acute monoblastic/monocytic leukemia, in relapse
- ;;^UTILITY(U,$J,358.3,1150,1,4,0)
- ;;=4^C93.02
- ;;^UTILITY(U,$J,358.3,1150,2)
- ;;=^5001821
- ;;^UTILITY(U,$J,358.3,1151,0)
- ;;=C93.10^^10^77^31
- ;;^UTILITY(U,$J,358.3,1151,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1151,1,3,0)
- ;;=3^Chronic myelomonocytic leukemia not achieve remission
- ;;^UTILITY(U,$J,358.3,1151,1,4,0)
- ;;=4^C93.10
- ;;^UTILITY(U,$J,358.3,1151,2)
- ;;=^5001822
- ;;^UTILITY(U,$J,358.3,1152,0)
- ;;=C93.11^^10^77^33
- ;;^UTILITY(U,$J,358.3,1152,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1152,1,3,0)
- ;;=3^Chronic myelomonocytic leukemia, in remission
- ;;^UTILITY(U,$J,358.3,1152,1,4,0)
- ;;=4^C93.11
- ;;^UTILITY(U,$J,358.3,1152,2)
- ;;=^5001823
- ;;^UTILITY(U,$J,358.3,1153,0)
- ;;=C93.12^^10^77^32
- ;;^UTILITY(U,$J,358.3,1153,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1153,1,3,0)
- ;;=3^Chronic myelomonocytic leukemia, in relapse
- ;;^UTILITY(U,$J,358.3,1153,1,4,0)
- ;;=4^C93.12
- ;;^UTILITY(U,$J,358.3,1153,2)
- ;;=^5001824
- ;;^UTILITY(U,$J,358.3,1154,0)
- ;;=C93.90^^10^77^48
- ;;^UTILITY(U,$J,358.3,1154,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1154,1,3,0)
- ;;=3^Monocytic leukemia, unsp, not having achieved remission
- ;;^UTILITY(U,$J,358.3,1154,1,4,0)
- ;;=4^C93.90
- ;;^UTILITY(U,$J,358.3,1154,2)
- ;;=^5001828
- ;;^UTILITY(U,$J,358.3,1155,0)
- ;;=C93.91^^10^77^50
- ;;^UTILITY(U,$J,358.3,1155,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1155,1,3,0)
- ;;=3^Monocytic leukemia, unspecified in remission
- ;;^UTILITY(U,$J,358.3,1155,1,4,0)
- ;;=4^C93.91
- ;;^UTILITY(U,$J,358.3,1155,2)
- ;;=^5001829
- ;;^UTILITY(U,$J,358.3,1156,0)
- ;;=C93.92^^10^77^49
- ;;^UTILITY(U,$J,358.3,1156,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1156,1,3,0)
- ;;=3^Monocytic leukemia, unspecified in relapse
- ;;^UTILITY(U,$J,358.3,1156,1,4,0)
- ;;=4^C93.92
- ;;^UTILITY(U,$J,358.3,1156,2)
- ;;=^5001830
- ;;^UTILITY(U,$J,358.3,1157,0)
- ;;=C94.00^^10^77^3
- ;;^UTILITY(U,$J,358.3,1157,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1157,1,3,0)
- ;;=3^Acute erythroid leukemia, not having achieved remission
- ;;^UTILITY(U,$J,358.3,1157,1,4,0)
- ;;=4^C94.00
- ;;^UTILITY(U,$J,358.3,1157,2)
- ;;=^5001834
- ;;^UTILITY(U,$J,358.3,1158,0)
- ;;=C94.01^^10^77^2
- ;;^UTILITY(U,$J,358.3,1158,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1158,1,3,0)
- ;;=3^Acute erythroid leukemia, in remission
- ;;^UTILITY(U,$J,358.3,1158,1,4,0)
- ;;=4^C94.01
- ;;^UTILITY(U,$J,358.3,1158,2)
- ;;=^5001835
- ;;^UTILITY(U,$J,358.3,1159,0)
- ;;=C94.02^^10^77^1
- ;;^UTILITY(U,$J,358.3,1159,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1159,1,3,0)
- ;;=3^Acute erythroid leukemia, in relapse
- ;;^UTILITY(U,$J,358.3,1159,1,4,0)
- ;;=4^C94.02
- ;;^UTILITY(U,$J,358.3,1159,2)
- ;;=^5001836
- ;;^UTILITY(U,$J,358.3,1160,0)
- ;;=C94.20^^10^77^7
- ;;^UTILITY(U,$J,358.3,1160,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1160,1,3,0)
- ;;=3^Acute megakaryoblastic leukemia not achieve remission
- ;;^UTILITY(U,$J,358.3,1160,1,4,0)
- ;;=4^C94.20
- ;;^UTILITY(U,$J,358.3,1160,2)
- ;;=^5001837
- ;;^UTILITY(U,$J,358.3,1161,0)
- ;;=C94.21^^10^77^9
- ;;^UTILITY(U,$J,358.3,1161,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1161,1,3,0)
- ;;=3^Acute megakaryoblastic leukemia, in remission
- ;;^UTILITY(U,$J,358.3,1161,1,4,0)
- ;;=4^C94.21
- ;;^UTILITY(U,$J,358.3,1161,2)
- ;;=^5001838
- ;;^UTILITY(U,$J,358.3,1162,0)
- ;;=C94.22^^10^77^8
- ;;^UTILITY(U,$J,358.3,1162,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1162,1,3,0)
- ;;=3^Acute megakaryoblastic leukemia, in relapse
- ;;^UTILITY(U,$J,358.3,1162,1,4,0)
- ;;=4^C94.22
- ;;^UTILITY(U,$J,358.3,1162,2)
- ;;=^5001839
- ;;^UTILITY(U,$J,358.3,1163,0)
- ;;=C94.30^^10^77^45
- ;;^UTILITY(U,$J,358.3,1163,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1163,1,3,0)
- ;;=3^Mast cell leukemia not having achieved remission
- ;;^UTILITY(U,$J,358.3,1163,1,4,0)
- ;;=4^C94.30
- ;;^UTILITY(U,$J,358.3,1163,2)
- ;;=^5001840
- ;;^UTILITY(U,$J,358.3,1164,0)
- ;;=C94.31^^10^77^47
- ;;^UTILITY(U,$J,358.3,1164,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1164,1,3,0)
- ;;=3^Mast cell leukemia, in remission
- ;;^UTILITY(U,$J,358.3,1164,1,4,0)
- ;;=4^C94.31
- ;;^UTILITY(U,$J,358.3,1164,2)
- ;;=^5001841
- ;;^UTILITY(U,$J,358.3,1165,0)
- ;;=C94.32^^10^77^46
- ;;^UTILITY(U,$J,358.3,1165,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1165,1,3,0)
- ;;=3^Mast cell leukemia, in relapse
- ;;^UTILITY(U,$J,358.3,1165,1,4,0)
- ;;=4^C94.32
- ;;^UTILITY(U,$J,358.3,1165,2)
- ;;=^5001842
- ;;^UTILITY(U,$J,358.3,1166,0)
- ;;=C95.00^^10^77^4
- ;;^UTILITY(U,$J,358.3,1166,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1166,1,3,0)
- ;;=3^Acute leukemia of unsp cell type not achieve remission
- ;;^UTILITY(U,$J,358.3,1166,1,4,0)
- ;;=4^C95.00
- ;;^UTILITY(U,$J,358.3,1166,2)
- ;;=^5001850
- ;;^UTILITY(U,$J,358.3,1167,0)
- ;;=C95.01^^10^77^5
- ;;^UTILITY(U,$J,358.3,1167,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1167,1,3,0)
- ;;=3^Acute leukemia of unspecified cell type, in remission
- ;;^UTILITY(U,$J,358.3,1167,1,4,0)
- ;;=4^C95.01
- ;;^UTILITY(U,$J,358.3,1167,2)
- ;;=^5001851
- ;;^UTILITY(U,$J,358.3,1168,0)
- ;;=C95.02^^10^77^6
- ;;^UTILITY(U,$J,358.3,1168,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1168,1,3,0)
- ;;=3^Acute leukemia of unspecified cell type, in relapse
- ;;^UTILITY(U,$J,358.3,1168,1,4,0)
- ;;=4^C95.02
- ;;^UTILITY(U,$J,358.3,1168,2)
- ;;=^5001852
- ;;^UTILITY(U,$J,358.3,1169,0)
- ;;=D45.^^10^77^58
- ;;^UTILITY(U,$J,358.3,1169,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1169,1,3,0)
- ;;=3^Polycythemia vera
- ;;^UTILITY(U,$J,358.3,1169,1,4,0)
- ;;=4^D45.
- ;;^UTILITY(U,$J,358.3,1169,2)
- ;;=^96105
- ;;^UTILITY(U,$J,358.3,1170,0)
- ;;=C95.10^^10^77^25
- ;;^UTILITY(U,$J,358.3,1170,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1170,1,3,0)
- ;;=3^Chronic leukemia of unsp cell type not achieve remission
- ;;^UTILITY(U,$J,358.3,1170,1,4,0)
- ;;=4^C95.10
- ;;^UTILITY(U,$J,358.3,1170,2)
- ;;=^5001853
- ;;^UTILITY(U,$J,358.3,1171,0)
- ;;=C95.11^^10^77^26
- ;;^UTILITY(U,$J,358.3,1171,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1171,1,3,0)
- ;;=3^Chronic leukemia of unspecified cell type, in remission
- ;;^UTILITY(U,$J,358.3,1171,1,4,0)
- ;;=4^C95.11
- ;;^UTILITY(U,$J,358.3,1171,2)
- ;;=^5001854
- ;;^UTILITY(U,$J,358.3,1172,0)
- ;;=C95.12^^10^77^27
- ;;^UTILITY(U,$J,358.3,1172,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1172,1,3,0)
- ;;=3^Chronic leukemia of unspecified cell type, in relapse
- ;;^UTILITY(U,$J,358.3,1172,1,4,0)
- ;;=4^C95.12
- ;;^UTILITY(U,$J,358.3,1172,2)
- ;;=^5001855
- ;;^UTILITY(U,$J,358.3,1173,0)
- ;;=D46.9^^10^77^51
- ;;^UTILITY(U,$J,358.3,1173,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1173,1,3,0)
- ;;=3^Myelodysplastic syndrome, unspecified
- ;;^UTILITY(U,$J,358.3,1173,1,4,0)
- ;;=4^D46.9
- ;;^UTILITY(U,$J,358.3,1173,2)
- ;;=^334031
- ;;^UTILITY(U,$J,358.3,1174,0)
- ;;=C95.90^^10^77^39
- ;;^UTILITY(U,$J,358.3,1174,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1174,1,3,0)
- ;;=3^Leukemia, unspecified not having achieved remission
- ;;^UTILITY(U,$J,358.3,1174,1,4,0)
- ;;=4^C95.90
- ;;^UTILITY(U,$J,358.3,1174,2)
- ;;=^5001856
- ;;^UTILITY(U,$J,358.3,1175,0)
- ;;=C95.91^^10^77^41
- ;;^UTILITY(U,$J,358.3,1175,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1175,1,3,0)
- ;;=3^Leukemia, unspecified, in remission
- ;;^UTILITY(U,$J,358.3,1175,1,4,0)
- ;;=4^C95.91
- ;;^UTILITY(U,$J,358.3,1175,2)
- ;;=^5001857
- ;;^UTILITY(U,$J,358.3,1176,0)
- ;;=C95.92^^10^77^40
- ;;^UTILITY(U,$J,358.3,1176,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1176,1,3,0)
- ;;=3^Leukemia, unspecified, in relapse
- ;;^UTILITY(U,$J,358.3,1176,1,4,0)
- ;;=4^C95.92
- ;;^UTILITY(U,$J,358.3,1176,2)
- ;;=^5001858
- ;;^UTILITY(U,$J,358.3,1177,0)
- ;;=D72.9^^10^77^35
- ;;^UTILITY(U,$J,358.3,1177,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1177,1,3,0)
- ;;=3^Disorder of white blood cells, unspecified
- ;;^UTILITY(U,$J,358.3,1177,1,4,0)
- ;;=4^D72.9
- ;;^UTILITY(U,$J,358.3,1177,2)
- ;;=^5002381
- ;;^UTILITY(U,$J,358.3,1178,0)
- ;;=D75.1^^10^77^59
- ;;^UTILITY(U,$J,358.3,1178,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1178,1,3,0)
- ;;=3^Secondary polycythemia
- ;;^UTILITY(U,$J,358.3,1178,1,4,0)
- ;;=4^D75.1
- ;;^UTILITY(U,$J,358.3,1178,2)
- ;;=^186856
- ;;^UTILITY(U,$J,358.3,1179,0)
- ;;=D75.9^^10^77^34
- ;;^UTILITY(U,$J,358.3,1179,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1179,1,3,0)
- ;;=3^Disease of blood and blood-forming organs, unspecified
- ;;^UTILITY(U,$J,358.3,1179,1,4,0)
- ;;=4^D75.9
- ;;^UTILITY(U,$J,358.3,1179,2)
- ;;=^5002393
- ;;^UTILITY(U,$J,358.3,1180,0)
- ;;=C7A.010^^10^77^42
- ;;^UTILITY(U,$J,358.3,1180,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1180,1,3,0)
- ;;=3^Malignant carcinoid tumor of the duodenum
- ;;^UTILITY(U,$J,358.3,1180,1,4,0)
- ;;=4^C7A.010
- ;;^UTILITY(U,$J,358.3,1180,2)
- ;;=^5001359
- ;;^UTILITY(U,$J,358.3,1181,0)
- ;;=C7A.011^^10^77^44
- ;;^UTILITY(U,$J,358.3,1181,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1181,1,3,0)
- ;;=3^Malignant carcinoid tumor of the jejunum
- ;;^UTILITY(U,$J,358.3,1181,1,4,0)
- ;;=4^C7A.011
- ;;^UTILITY(U,$J,358.3,1181,2)
- ;;=^5001360
- ;;^UTILITY(U,$J,358.3,1182,0)
- ;;=C7A.012^^10^77^43
- ;;^UTILITY(U,$J,358.3,1182,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1182,1,3,0)
- ;;=3^Malignant carcinoid tumor of the ileum
- ;;^UTILITY(U,$J,358.3,1182,1,4,0)
- ;;=4^C7A.012
- ;;^UTILITY(U,$J,358.3,1182,2)
- ;;=^5001361
- ;;^UTILITY(U,$J,358.3,1183,0)
- ;;=C93.30^^10^77^38
- ;;^UTILITY(U,$J,358.3,1183,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1183,1,3,0)
- ;;=3^Juvenile myelomonocytic leukemia,no remission
- ;;^UTILITY(U,$J,358.3,1183,1,4,0)
- ;;=4^C93.30
- ;;^UTILITY(U,$J,358.3,1183,2)
- ;;=^5001825
- ;;^UTILITY(U,$J,358.3,1184,0)
- ;;=C93.31^^10^77^37
- ;;^UTILITY(U,$J,358.3,1184,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1184,1,3,0)
- ;;=3^Juvenile myelomonocytic leukemia,in remission
- ;;^UTILITY(U,$J,358.3,1184,1,4,0)
- ;;=4^C93.31
- ;;^UTILITY(U,$J,358.3,1184,2)
- ;;=^5001826
- ;;^UTILITY(U,$J,358.3,1185,0)
- ;;=C93.32^^10^77^36
- ;;^UTILITY(U,$J,358.3,1185,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1185,1,3,0)
- ;;=3^Juvenile myelomonocytic leukemia,in relapse
- ;;^UTILITY(U,$J,358.3,1185,1,4,0)
- ;;=4^C93.32
- ;;^UTILITY(U,$J,358.3,1185,2)
- ;;=^5001827
- ;;^UTILITY(U,$J,358.3,1186,0)
- ;;=D48.0^^10^78^5
- ;;^UTILITY(U,$J,358.3,1186,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1186,1,3,0)
- ;;=3^Neoplasm of uncertain behavior of bone/artic cartl
- ;;^UTILITY(U,$J,358.3,1186,1,4,0)
- ;;=4^D48.0
- ;;^UTILITY(U,$J,358.3,1186,2)
- ;;=^81953
- ;;^UTILITY(U,$J,358.3,1187,0)
- ;;=D48.1^^10^78^6
- ;;^UTILITY(U,$J,358.3,1187,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1187,1,3,0)
- ;;=3^Neoplasm of uncertain behavior of connctv/soft tiss
- ;;^UTILITY(U,$J,358.3,1187,1,4,0)
- ;;=4^D48.1
- ;;^UTILITY(U,$J,358.3,1187,2)
- ;;=^267776
- ;;^UTILITY(U,$J,358.3,1188,0)
- ;;=D48.5^^10^78^10
- ;;^UTILITY(U,$J,358.3,1188,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1188,1,3,0)
- ;;=3^Neoplasm of uncertain behavior of skin
- ;;^UTILITY(U,$J,358.3,1188,1,4,0)
- ;;=4^D48.5
- ;;^UTILITY(U,$J,358.3,1188,2)
- ;;=^267777
- ;;^UTILITY(U,$J,358.3,1189,0)
- ;;=D48.61^^10^78^9
- ;;^UTILITY(U,$J,358.3,1189,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1189,1,3,0)
- ;;=3^Neoplasm of uncertain behavior of right breast
- ;;^UTILITY(U,$J,358.3,1189,1,4,0)
- ;;=4^D48.61
- ;;^UTILITY(U,$J,358.3,1189,2)
- ;;=^5002267
- ;;^UTILITY(U,$J,358.3,1190,0)
- ;;=D48.62^^10^78^7
- ;;^UTILITY(U,$J,358.3,1190,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1190,1,3,0)
- ;;=3^Neoplasm of uncertain behavior of left breast
- ;;^UTILITY(U,$J,358.3,1190,1,4,0)
- ;;=4^D48.62
- ;;^UTILITY(U,$J,358.3,1190,2)
- ;;=^5002268
- ;;^UTILITY(U,$J,358.3,1191,0)
- ;;=D46.0^^10^78^18
- ;;^UTILITY(U,$J,358.3,1191,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1191,1,3,0)
- ;;=3^Refractory anemia without ring sideroblasts, so stated
- ;;^UTILITY(U,$J,358.3,1191,1,4,0)
- ;;=4^D46.0
- ;;^UTILITY(U,$J,358.3,1191,2)
- ;;=^5002245
- ;;^UTILITY(U,$J,358.3,1192,0)
- ;;=D46.1^^10^78^17
- ;;^UTILITY(U,$J,358.3,1192,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1192,1,3,0)
- ;;=3^Refractory anemia with ring sideroblasts
- ;;^UTILITY(U,$J,358.3,1192,1,4,0)
- ;;=4^D46.1
- ;;^UTILITY(U,$J,358.3,1192,2)
- ;;=^5002246
- ;;^UTILITY(U,$J,358.3,1193,0)
- ;;=D46.20^^10^78^14
- ;;^UTILITY(U,$J,358.3,1193,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1193,1,3,0)
- ;;=3^Refractory anemia with excess of blasts, unspecified
- ;;^UTILITY(U,$J,358.3,1193,1,4,0)
- ;;=4^D46.20
- ;;^UTILITY(U,$J,358.3,1193,2)
- ;;=^5002247
- ;;^UTILITY(U,$J,358.3,1194,0)
- ;;=D46.21^^10^78^15
- ;;^UTILITY(U,$J,358.3,1194,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1194,1,3,0)
- ;;=3^Refractory anemia with excess of blasts 1
- ;;^UTILITY(U,$J,358.3,1194,1,4,0)
- ;;=4^D46.21
- ;;^UTILITY(U,$J,358.3,1194,2)
- ;;=^5002248
- ;;^UTILITY(U,$J,358.3,1195,0)
- ;;=D46.A^^10^78^19
- ;;^UTILITY(U,$J,358.3,1195,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1195,1,3,0)
- ;;=3^Refractory cytopenia with multilineage dysplasia
- ;;^UTILITY(U,$J,358.3,1195,1,4,0)
- ;;=4^D46.A
- ;;^UTILITY(U,$J,358.3,1195,2)
- ;;=^5002251
- ;;^UTILITY(U,$J,358.3,1196,0)
- ;;=D46.B^^10^78^13
- ;;^UTILITY(U,$J,358.3,1196,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1196,1,3,0)
- ;;=3^Refract cytopenia w multilin dysplasia and ring sideroblasts
- ;;^UTILITY(U,$J,358.3,1196,1,4,0)
- ;;=4^D46.B
- ;;^UTILITY(U,$J,358.3,1196,2)
- ;;=^5002252
- ;;^UTILITY(U,$J,358.3,1197,0)
- ;;=D46.22^^10^78^16
- ;;^UTILITY(U,$J,358.3,1197,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1197,1,3,0)
- ;;=3^Refractory anemia with excess of blasts 2
- ;;^UTILITY(U,$J,358.3,1197,1,4,0)
- ;;=4^D46.22
- ;;^UTILITY(U,$J,358.3,1197,2)
- ;;=^5002249
- ;;^UTILITY(U,$J,358.3,1198,0)
- ;;=D46.C^^10^78^3
- ;;^UTILITY(U,$J,358.3,1198,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1198,1,3,0)
- ;;=3^Myelodysplastic syndrome w isolated del(5q) chromsoml abnlt
- ;;^UTILITY(U,$J,358.3,1198,1,4,0)
- ;;=4^D46.C
- ;;^UTILITY(U,$J,358.3,1198,2)
- ;;=^5002253
- ;;^UTILITY(U,$J,358.3,1199,0)
- ;;=D46.9^^10^78^4
- ;;^UTILITY(U,$J,358.3,1199,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1199,1,3,0)
- ;;=3^Myelodysplastic syndrome, unspecified
- ;;^UTILITY(U,$J,358.3,1199,1,4,0)
- ;;=4^D46.9
- ;;^UTILITY(U,$J,358.3,1199,2)
- ;;=^334031
- ;;^UTILITY(U,$J,358.3,1200,0)
- ;;=D47.1^^10^78^1
- ;;^UTILITY(U,$J,358.3,1200,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1200,1,3,0)
- ;;=3^Chronic myeloproliferative disease
- ;;^UTILITY(U,$J,358.3,1200,1,4,0)
- ;;=4^D47.1
- ;;^UTILITY(U,$J,358.3,1200,2)
- ;;=^5002256
- ;;^UTILITY(U,$J,358.3,1201,0)
- ;;=D47.Z1^^10^78^12
- ;;^UTILITY(U,$J,358.3,1201,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1201,1,3,0)
- ;;=3^Post-transplant lymphoproliferative disorder (PTLD)
- ;;^UTILITY(U,$J,358.3,1201,1,4,0)
- ;;=4^D47.Z1
- ;;^UTILITY(U,$J,358.3,1201,2)
- ;;=^5002261
- ;;^UTILITY(U,$J,358.3,1202,0)
- ;;=D48.7^^10^78^8
- ;;^UTILITY(U,$J,358.3,1202,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,1202,1,3,0)
- ;;=3^Neoplasm of uncertain behavior of other specified sites
- ;;^UTILITY(U,$J,358.3,1202,1,4,0)
- ;;=4^D48.7
- ;;^UTILITY(U,$J,358.3,1202,2)
- ;;=^267779
- ;;^UTILITY(U,$J,358.3,1203,0)
- ;;=D48.9^^10^78^11
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI00P 19768 printed Feb 18, 2025@23:05:42 Page 2
- IBDEI00P ; ; 01-AUG-2022
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,1136,1,3,0)
- +2 ;;=3^Chronic myeloid leuk, BCR/ABL-positive, not achieve remis
- +3 ;;^UTILITY(U,$J,358.3,1136,1,4,0)
- +4 ;;=4^C92.10
- +5 ;;^UTILITY(U,$J,358.3,1136,2)
- +6 ;;=^5001792
- +7 ;;^UTILITY(U,$J,358.3,1137,0)
- +8 ;;=C92.11^^10^77^29
- +9 ;;^UTILITY(U,$J,358.3,1137,1,0)
- +10 ;;=^358.31IA^4^2
- +11 ;;^UTILITY(U,$J,358.3,1137,1,3,0)
- +12 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in remission
- +13 ;;^UTILITY(U,$J,358.3,1137,1,4,0)
- +14 ;;=4^C92.11
- +15 ;;^UTILITY(U,$J,358.3,1137,2)
- +16 ;;=^5001793
- +17 ;;^UTILITY(U,$J,358.3,1138,0)
- +18 ;;=C92.12^^10^77^30
- +19 ;;^UTILITY(U,$J,358.3,1138,1,0)
- +20 ;;=^358.31IA^4^2
- +21 ;;^UTILITY(U,$J,358.3,1138,1,3,0)
- +22 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in relapse
- +23 ;;^UTILITY(U,$J,358.3,1138,1,4,0)
- +24 ;;=4^C92.12
- +25 ;;^UTILITY(U,$J,358.3,1138,2)
- +26 ;;=^5001794
- +27 ;;^UTILITY(U,$J,358.3,1139,0)
- +28 ;;=C92.20^^10^77^22
- +29 ;;^UTILITY(U,$J,358.3,1139,1,0)
- +30 ;;=^358.31IA^4^2
- +31 ;;^UTILITY(U,$J,358.3,1139,1,3,0)
- +32 ;;=3^Atyp chronic myeloid leuk, BCR/ABL-neg, not achieve remis
- +33 ;;^UTILITY(U,$J,358.3,1139,1,4,0)
- +34 ;;=4^C92.20
- +35 ;;^UTILITY(U,$J,358.3,1139,2)
- +36 ;;=^5001795
- +37 ;;^UTILITY(U,$J,358.3,1140,0)
- +38 ;;=C92.21^^10^77^23
- +39 ;;^UTILITY(U,$J,358.3,1140,1,0)
- +40 ;;=^358.31IA^4^2
- +41 ;;^UTILITY(U,$J,358.3,1140,1,3,0)
- +42 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
- +43 ;;^UTILITY(U,$J,358.3,1140,1,4,0)
- +44 ;;=4^C92.21
- +45 ;;^UTILITY(U,$J,358.3,1140,2)
- +46 ;;=^5001796
- +47 ;;^UTILITY(U,$J,358.3,1141,0)
- +48 ;;=C92.22^^10^77^24
- +49 ;;^UTILITY(U,$J,358.3,1141,1,0)
- +50 ;;=^358.31IA^4^2
- +51 ;;^UTILITY(U,$J,358.3,1141,1,3,0)
- +52 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
- +53 ;;^UTILITY(U,$J,358.3,1141,1,4,0)
- +54 ;;=4^C92.22
- +55 ;;^UTILITY(U,$J,358.3,1141,2)
- +56 ;;=^5001797
- +57 ;;^UTILITY(U,$J,358.3,1142,0)
- +58 ;;=C92.30^^10^77^57
- +59 ;;^UTILITY(U,$J,358.3,1142,1,0)
- +60 ;;=^358.31IA^4^2
- +61 ;;^UTILITY(U,$J,358.3,1142,1,3,0)
- +62 ;;=3^Myeloid sarcoma, not having achieved remission
- +63 ;;^UTILITY(U,$J,358.3,1142,1,4,0)
- +64 ;;=4^C92.30
- +65 ;;^UTILITY(U,$J,358.3,1142,2)
- +66 ;;=^5001798
- +67 ;;^UTILITY(U,$J,358.3,1143,0)
- +68 ;;=C92.31^^10^77^56
- +69 ;;^UTILITY(U,$J,358.3,1143,1,0)
- +70 ;;=^358.31IA^4^2
- +71 ;;^UTILITY(U,$J,358.3,1143,1,3,0)
- +72 ;;=3^Myeloid sarcoma, in remission
- +73 ;;^UTILITY(U,$J,358.3,1143,1,4,0)
- +74 ;;=4^C92.31
- +75 ;;^UTILITY(U,$J,358.3,1143,2)
- +76 ;;=^5001799
- +77 ;;^UTILITY(U,$J,358.3,1144,0)
- +78 ;;=C92.32^^10^77^55
- +79 ;;^UTILITY(U,$J,358.3,1144,1,0)
- +80 ;;=^358.31IA^4^2
- +81 ;;^UTILITY(U,$J,358.3,1144,1,3,0)
- +82 ;;=3^Myeloid sarcoma, in relapse
- +83 ;;^UTILITY(U,$J,358.3,1144,1,4,0)
- +84 ;;=4^C92.32
- +85 ;;^UTILITY(U,$J,358.3,1144,2)
- +86 ;;=^5001800
- +87 ;;^UTILITY(U,$J,358.3,1145,0)
- +88 ;;=C92.90^^10^77^54
- +89 ;;^UTILITY(U,$J,358.3,1145,1,0)
- +90 ;;=^358.31IA^4^2
- +91 ;;^UTILITY(U,$J,358.3,1145,1,3,0)
- +92 ;;=3^Myeloid leukemia, unspecified, not having achieved remission
- +93 ;;^UTILITY(U,$J,358.3,1145,1,4,0)
- +94 ;;=4^C92.90
- +95 ;;^UTILITY(U,$J,358.3,1145,2)
- +96 ;;=^5001810
- +97 ;;^UTILITY(U,$J,358.3,1146,0)
- +98 ;;=C92.91^^10^77^53
- +99 ;;^UTILITY(U,$J,358.3,1146,1,0)
- +100 ;;=^358.31IA^4^2
- +101 ;;^UTILITY(U,$J,358.3,1146,1,3,0)
- +102 ;;=3^Myeloid leukemia, unspecified in remission
- +103 ;;^UTILITY(U,$J,358.3,1146,1,4,0)
- +104 ;;=4^C92.91
- +105 ;;^UTILITY(U,$J,358.3,1146,2)
- +106 ;;=^5001811
- +107 ;;^UTILITY(U,$J,358.3,1147,0)
- +108 ;;=C92.92^^10^77^52
- +109 ;;^UTILITY(U,$J,358.3,1147,1,0)
- +110 ;;=^358.31IA^4^2
- +111 ;;^UTILITY(U,$J,358.3,1147,1,3,0)
- +112 ;;=3^Myeloid leukemia, unspecified in relapse
- +113 ;;^UTILITY(U,$J,358.3,1147,1,4,0)
- +114 ;;=4^C92.92
- +115 ;;^UTILITY(U,$J,358.3,1147,2)
- +116 ;;=^5001812
- +117 ;;^UTILITY(U,$J,358.3,1148,0)
- +118 ;;=C93.00^^10^77^12
- +119 ;;^UTILITY(U,$J,358.3,1148,1,0)
- +120 ;;=^358.31IA^4^2
- +121 ;;^UTILITY(U,$J,358.3,1148,1,3,0)
- +122 ;;=3^Acute monoblastic/monocytic leukemia, not achieve remission
- +123 ;;^UTILITY(U,$J,358.3,1148,1,4,0)
- +124 ;;=4^C93.00
- +125 ;;^UTILITY(U,$J,358.3,1148,2)
- +126 ;;=^5001819
- +127 ;;^UTILITY(U,$J,358.3,1149,0)
- +128 ;;=C93.01^^10^77^10
- +129 ;;^UTILITY(U,$J,358.3,1149,1,0)
- +130 ;;=^358.31IA^4^2
- +131 ;;^UTILITY(U,$J,358.3,1149,1,3,0)
- +132 ;;=3^Acute monoblastic/monocytic leukemia, in remission
- +133 ;;^UTILITY(U,$J,358.3,1149,1,4,0)
- +134 ;;=4^C93.01
- +135 ;;^UTILITY(U,$J,358.3,1149,2)
- +136 ;;=^5001820
- +137 ;;^UTILITY(U,$J,358.3,1150,0)
- +138 ;;=C93.02^^10^77^11
- +139 ;;^UTILITY(U,$J,358.3,1150,1,0)
- +140 ;;=^358.31IA^4^2
- +141 ;;^UTILITY(U,$J,358.3,1150,1,3,0)
- +142 ;;=3^Acute monoblastic/monocytic leukemia, in relapse
- +143 ;;^UTILITY(U,$J,358.3,1150,1,4,0)
- +144 ;;=4^C93.02
- +145 ;;^UTILITY(U,$J,358.3,1150,2)
- +146 ;;=^5001821
- +147 ;;^UTILITY(U,$J,358.3,1151,0)
- +148 ;;=C93.10^^10^77^31
- +149 ;;^UTILITY(U,$J,358.3,1151,1,0)
- +150 ;;=^358.31IA^4^2
- +151 ;;^UTILITY(U,$J,358.3,1151,1,3,0)
- +152 ;;=3^Chronic myelomonocytic leukemia not achieve remission
- +153 ;;^UTILITY(U,$J,358.3,1151,1,4,0)
- +154 ;;=4^C93.10
- +155 ;;^UTILITY(U,$J,358.3,1151,2)
- +156 ;;=^5001822
- +157 ;;^UTILITY(U,$J,358.3,1152,0)
- +158 ;;=C93.11^^10^77^33
- +159 ;;^UTILITY(U,$J,358.3,1152,1,0)
- +160 ;;=^358.31IA^4^2
- +161 ;;^UTILITY(U,$J,358.3,1152,1,3,0)
- +162 ;;=3^Chronic myelomonocytic leukemia, in remission
- +163 ;;^UTILITY(U,$J,358.3,1152,1,4,0)
- +164 ;;=4^C93.11
- +165 ;;^UTILITY(U,$J,358.3,1152,2)
- +166 ;;=^5001823
- +167 ;;^UTILITY(U,$J,358.3,1153,0)
- +168 ;;=C93.12^^10^77^32
- +169 ;;^UTILITY(U,$J,358.3,1153,1,0)
- +170 ;;=^358.31IA^4^2
- +171 ;;^UTILITY(U,$J,358.3,1153,1,3,0)
- +172 ;;=3^Chronic myelomonocytic leukemia, in relapse
- +173 ;;^UTILITY(U,$J,358.3,1153,1,4,0)
- +174 ;;=4^C93.12
- +175 ;;^UTILITY(U,$J,358.3,1153,2)
- +176 ;;=^5001824
- +177 ;;^UTILITY(U,$J,358.3,1154,0)
- +178 ;;=C93.90^^10^77^48
- +179 ;;^UTILITY(U,$J,358.3,1154,1,0)
- +180 ;;=^358.31IA^4^2
- +181 ;;^UTILITY(U,$J,358.3,1154,1,3,0)
- +182 ;;=3^Monocytic leukemia, unsp, not having achieved remission
- +183 ;;^UTILITY(U,$J,358.3,1154,1,4,0)
- +184 ;;=4^C93.90
- +185 ;;^UTILITY(U,$J,358.3,1154,2)
- +186 ;;=^5001828
- +187 ;;^UTILITY(U,$J,358.3,1155,0)
- +188 ;;=C93.91^^10^77^50
- +189 ;;^UTILITY(U,$J,358.3,1155,1,0)
- +190 ;;=^358.31IA^4^2
- +191 ;;^UTILITY(U,$J,358.3,1155,1,3,0)
- +192 ;;=3^Monocytic leukemia, unspecified in remission
- +193 ;;^UTILITY(U,$J,358.3,1155,1,4,0)
- +194 ;;=4^C93.91
- +195 ;;^UTILITY(U,$J,358.3,1155,2)
- +196 ;;=^5001829
- +197 ;;^UTILITY(U,$J,358.3,1156,0)
- +198 ;;=C93.92^^10^77^49
- +199 ;;^UTILITY(U,$J,358.3,1156,1,0)
- +200 ;;=^358.31IA^4^2
- +201 ;;^UTILITY(U,$J,358.3,1156,1,3,0)
- +202 ;;=3^Monocytic leukemia, unspecified in relapse
- +203 ;;^UTILITY(U,$J,358.3,1156,1,4,0)
- +204 ;;=4^C93.92
- +205 ;;^UTILITY(U,$J,358.3,1156,2)
- +206 ;;=^5001830
- +207 ;;^UTILITY(U,$J,358.3,1157,0)
- +208 ;;=C94.00^^10^77^3
- +209 ;;^UTILITY(U,$J,358.3,1157,1,0)
- +210 ;;=^358.31IA^4^2
- +211 ;;^UTILITY(U,$J,358.3,1157,1,3,0)
- +212 ;;=3^Acute erythroid leukemia, not having achieved remission
- +213 ;;^UTILITY(U,$J,358.3,1157,1,4,0)
- +214 ;;=4^C94.00
- +215 ;;^UTILITY(U,$J,358.3,1157,2)
- +216 ;;=^5001834
- +217 ;;^UTILITY(U,$J,358.3,1158,0)
- +218 ;;=C94.01^^10^77^2
- +219 ;;^UTILITY(U,$J,358.3,1158,1,0)
- +220 ;;=^358.31IA^4^2
- +221 ;;^UTILITY(U,$J,358.3,1158,1,3,0)
- +222 ;;=3^Acute erythroid leukemia, in remission
- +223 ;;^UTILITY(U,$J,358.3,1158,1,4,0)
- +224 ;;=4^C94.01
- +225 ;;^UTILITY(U,$J,358.3,1158,2)
- +226 ;;=^5001835
- +227 ;;^UTILITY(U,$J,358.3,1159,0)
- +228 ;;=C94.02^^10^77^1
- +229 ;;^UTILITY(U,$J,358.3,1159,1,0)
- +230 ;;=^358.31IA^4^2
- +231 ;;^UTILITY(U,$J,358.3,1159,1,3,0)
- +232 ;;=3^Acute erythroid leukemia, in relapse
- +233 ;;^UTILITY(U,$J,358.3,1159,1,4,0)
- +234 ;;=4^C94.02
- +235 ;;^UTILITY(U,$J,358.3,1159,2)
- +236 ;;=^5001836
- +237 ;;^UTILITY(U,$J,358.3,1160,0)
- +238 ;;=C94.20^^10^77^7
- +239 ;;^UTILITY(U,$J,358.3,1160,1,0)
- +240 ;;=^358.31IA^4^2
- +241 ;;^UTILITY(U,$J,358.3,1160,1,3,0)
- +242 ;;=3^Acute megakaryoblastic leukemia not achieve remission
- +243 ;;^UTILITY(U,$J,358.3,1160,1,4,0)
- +244 ;;=4^C94.20
- +245 ;;^UTILITY(U,$J,358.3,1160,2)
- +246 ;;=^5001837
- +247 ;;^UTILITY(U,$J,358.3,1161,0)
- +248 ;;=C94.21^^10^77^9
- +249 ;;^UTILITY(U,$J,358.3,1161,1,0)
- +250 ;;=^358.31IA^4^2
- +251 ;;^UTILITY(U,$J,358.3,1161,1,3,0)
- +252 ;;=3^Acute megakaryoblastic leukemia, in remission
- +253 ;;^UTILITY(U,$J,358.3,1161,1,4,0)
- +254 ;;=4^C94.21
- +255 ;;^UTILITY(U,$J,358.3,1161,2)
- +256 ;;=^5001838
- +257 ;;^UTILITY(U,$J,358.3,1162,0)
- +258 ;;=C94.22^^10^77^8
- +259 ;;^UTILITY(U,$J,358.3,1162,1,0)
- +260 ;;=^358.31IA^4^2
- +261 ;;^UTILITY(U,$J,358.3,1162,1,3,0)
- +262 ;;=3^Acute megakaryoblastic leukemia, in relapse
- +263 ;;^UTILITY(U,$J,358.3,1162,1,4,0)
- +264 ;;=4^C94.22
- +265 ;;^UTILITY(U,$J,358.3,1162,2)
- +266 ;;=^5001839
- +267 ;;^UTILITY(U,$J,358.3,1163,0)
- +268 ;;=C94.30^^10^77^45
- +269 ;;^UTILITY(U,$J,358.3,1163,1,0)
- +270 ;;=^358.31IA^4^2
- +271 ;;^UTILITY(U,$J,358.3,1163,1,3,0)
- +272 ;;=3^Mast cell leukemia not having achieved remission
- +273 ;;^UTILITY(U,$J,358.3,1163,1,4,0)
- +274 ;;=4^C94.30
- +275 ;;^UTILITY(U,$J,358.3,1163,2)
- +276 ;;=^5001840
- +277 ;;^UTILITY(U,$J,358.3,1164,0)
- +278 ;;=C94.31^^10^77^47
- +279 ;;^UTILITY(U,$J,358.3,1164,1,0)
- +280 ;;=^358.31IA^4^2
- +281 ;;^UTILITY(U,$J,358.3,1164,1,3,0)
- +282 ;;=3^Mast cell leukemia, in remission
- +283 ;;^UTILITY(U,$J,358.3,1164,1,4,0)
- +284 ;;=4^C94.31
- +285 ;;^UTILITY(U,$J,358.3,1164,2)
- +286 ;;=^5001841
- +287 ;;^UTILITY(U,$J,358.3,1165,0)
- +288 ;;=C94.32^^10^77^46
- +289 ;;^UTILITY(U,$J,358.3,1165,1,0)
- +290 ;;=^358.31IA^4^2
- +291 ;;^UTILITY(U,$J,358.3,1165,1,3,0)
- +292 ;;=3^Mast cell leukemia, in relapse
- +293 ;;^UTILITY(U,$J,358.3,1165,1,4,0)
- +294 ;;=4^C94.32
- +295 ;;^UTILITY(U,$J,358.3,1165,2)
- +296 ;;=^5001842
- +297 ;;^UTILITY(U,$J,358.3,1166,0)
- +298 ;;=C95.00^^10^77^4
- +299 ;;^UTILITY(U,$J,358.3,1166,1,0)
- +300 ;;=^358.31IA^4^2
- +301 ;;^UTILITY(U,$J,358.3,1166,1,3,0)
- +302 ;;=3^Acute leukemia of unsp cell type not achieve remission
- +303 ;;^UTILITY(U,$J,358.3,1166,1,4,0)
- +304 ;;=4^C95.00
- +305 ;;^UTILITY(U,$J,358.3,1166,2)
- +306 ;;=^5001850
- +307 ;;^UTILITY(U,$J,358.3,1167,0)
- +308 ;;=C95.01^^10^77^5
- +309 ;;^UTILITY(U,$J,358.3,1167,1,0)
- +310 ;;=^358.31IA^4^2
- +311 ;;^UTILITY(U,$J,358.3,1167,1,3,0)
- +312 ;;=3^Acute leukemia of unspecified cell type, in remission
- +313 ;;^UTILITY(U,$J,358.3,1167,1,4,0)
- +314 ;;=4^C95.01
- +315 ;;^UTILITY(U,$J,358.3,1167,2)
- +316 ;;=^5001851
- +317 ;;^UTILITY(U,$J,358.3,1168,0)
- +318 ;;=C95.02^^10^77^6
- +319 ;;^UTILITY(U,$J,358.3,1168,1,0)
- +320 ;;=^358.31IA^4^2
- +321 ;;^UTILITY(U,$J,358.3,1168,1,3,0)
- +322 ;;=3^Acute leukemia of unspecified cell type, in relapse
- +323 ;;^UTILITY(U,$J,358.3,1168,1,4,0)
- +324 ;;=4^C95.02
- +325 ;;^UTILITY(U,$J,358.3,1168,2)
- +326 ;;=^5001852
- +327 ;;^UTILITY(U,$J,358.3,1169,0)
- +328 ;;=D45.^^10^77^58
- +329 ;;^UTILITY(U,$J,358.3,1169,1,0)
- +330 ;;=^358.31IA^4^2
- +331 ;;^UTILITY(U,$J,358.3,1169,1,3,0)
- +332 ;;=3^Polycythemia vera
- +333 ;;^UTILITY(U,$J,358.3,1169,1,4,0)
- +334 ;;=4^D45.
- +335 ;;^UTILITY(U,$J,358.3,1169,2)
- +336 ;;=^96105
- +337 ;;^UTILITY(U,$J,358.3,1170,0)
- +338 ;;=C95.10^^10^77^25
- +339 ;;^UTILITY(U,$J,358.3,1170,1,0)
- +340 ;;=^358.31IA^4^2
- +341 ;;^UTILITY(U,$J,358.3,1170,1,3,0)
- +342 ;;=3^Chronic leukemia of unsp cell type not achieve remission
- +343 ;;^UTILITY(U,$J,358.3,1170,1,4,0)
- +344 ;;=4^C95.10
- +345 ;;^UTILITY(U,$J,358.3,1170,2)
- +346 ;;=^5001853
- +347 ;;^UTILITY(U,$J,358.3,1171,0)
- +348 ;;=C95.11^^10^77^26
- +349 ;;^UTILITY(U,$J,358.3,1171,1,0)
- +350 ;;=^358.31IA^4^2
- +351 ;;^UTILITY(U,$J,358.3,1171,1,3,0)
- +352 ;;=3^Chronic leukemia of unspecified cell type, in remission
- +353 ;;^UTILITY(U,$J,358.3,1171,1,4,0)
- +354 ;;=4^C95.11
- +355 ;;^UTILITY(U,$J,358.3,1171,2)
- +356 ;;=^5001854
- +357 ;;^UTILITY(U,$J,358.3,1172,0)
- +358 ;;=C95.12^^10^77^27
- +359 ;;^UTILITY(U,$J,358.3,1172,1,0)
- +360 ;;=^358.31IA^4^2
- +361 ;;^UTILITY(U,$J,358.3,1172,1,3,0)
- +362 ;;=3^Chronic leukemia of unspecified cell type, in relapse
- +363 ;;^UTILITY(U,$J,358.3,1172,1,4,0)
- +364 ;;=4^C95.12
- +365 ;;^UTILITY(U,$J,358.3,1172,2)
- +366 ;;=^5001855
- +367 ;;^UTILITY(U,$J,358.3,1173,0)
- +368 ;;=D46.9^^10^77^51
- +369 ;;^UTILITY(U,$J,358.3,1173,1,0)
- +370 ;;=^358.31IA^4^2
- +371 ;;^UTILITY(U,$J,358.3,1173,1,3,0)
- +372 ;;=3^Myelodysplastic syndrome, unspecified
- +373 ;;^UTILITY(U,$J,358.3,1173,1,4,0)
- +374 ;;=4^D46.9
- +375 ;;^UTILITY(U,$J,358.3,1173,2)
- +376 ;;=^334031
- +377 ;;^UTILITY(U,$J,358.3,1174,0)
- +378 ;;=C95.90^^10^77^39
- +379 ;;^UTILITY(U,$J,358.3,1174,1,0)
- +380 ;;=^358.31IA^4^2
- +381 ;;^UTILITY(U,$J,358.3,1174,1,3,0)
- +382 ;;=3^Leukemia, unspecified not having achieved remission
- +383 ;;^UTILITY(U,$J,358.3,1174,1,4,0)
- +384 ;;=4^C95.90
- +385 ;;^UTILITY(U,$J,358.3,1174,2)
- +386 ;;=^5001856
- +387 ;;^UTILITY(U,$J,358.3,1175,0)
- +388 ;;=C95.91^^10^77^41
- +389 ;;^UTILITY(U,$J,358.3,1175,1,0)
- +390 ;;=^358.31IA^4^2
- +391 ;;^UTILITY(U,$J,358.3,1175,1,3,0)
- +392 ;;=3^Leukemia, unspecified, in remission
- +393 ;;^UTILITY(U,$J,358.3,1175,1,4,0)
- +394 ;;=4^C95.91
- +395 ;;^UTILITY(U,$J,358.3,1175,2)
- +396 ;;=^5001857
- +397 ;;^UTILITY(U,$J,358.3,1176,0)
- +398 ;;=C95.92^^10^77^40
- +399 ;;^UTILITY(U,$J,358.3,1176,1,0)
- +400 ;;=^358.31IA^4^2
- +401 ;;^UTILITY(U,$J,358.3,1176,1,3,0)
- +402 ;;=3^Leukemia, unspecified, in relapse
- +403 ;;^UTILITY(U,$J,358.3,1176,1,4,0)
- +404 ;;=4^C95.92
- +405 ;;^UTILITY(U,$J,358.3,1176,2)
- +406 ;;=^5001858
- +407 ;;^UTILITY(U,$J,358.3,1177,0)
- +408 ;;=D72.9^^10^77^35
- +409 ;;^UTILITY(U,$J,358.3,1177,1,0)
- +410 ;;=^358.31IA^4^2
- +411 ;;^UTILITY(U,$J,358.3,1177,1,3,0)
- +412 ;;=3^Disorder of white blood cells, unspecified
- +413 ;;^UTILITY(U,$J,358.3,1177,1,4,0)
- +414 ;;=4^D72.9
- +415 ;;^UTILITY(U,$J,358.3,1177,2)
- +416 ;;=^5002381
- +417 ;;^UTILITY(U,$J,358.3,1178,0)
- +418 ;;=D75.1^^10^77^59
- +419 ;;^UTILITY(U,$J,358.3,1178,1,0)
- +420 ;;=^358.31IA^4^2
- +421 ;;^UTILITY(U,$J,358.3,1178,1,3,0)
- +422 ;;=3^Secondary polycythemia
- +423 ;;^UTILITY(U,$J,358.3,1178,1,4,0)
- +424 ;;=4^D75.1
- +425 ;;^UTILITY(U,$J,358.3,1178,2)
- +426 ;;=^186856
- +427 ;;^UTILITY(U,$J,358.3,1179,0)
- +428 ;;=D75.9^^10^77^34
- +429 ;;^UTILITY(U,$J,358.3,1179,1,0)
- +430 ;;=^358.31IA^4^2
- +431 ;;^UTILITY(U,$J,358.3,1179,1,3,0)
- +432 ;;=3^Disease of blood and blood-forming organs, unspecified
- +433 ;;^UTILITY(U,$J,358.3,1179,1,4,0)
- +434 ;;=4^D75.9
- +435 ;;^UTILITY(U,$J,358.3,1179,2)
- +436 ;;=^5002393
- +437 ;;^UTILITY(U,$J,358.3,1180,0)
- +438 ;;=C7A.010^^10^77^42
- +439 ;;^UTILITY(U,$J,358.3,1180,1,0)
- +440 ;;=^358.31IA^4^2
- +441 ;;^UTILITY(U,$J,358.3,1180,1,3,0)
- +442 ;;=3^Malignant carcinoid tumor of the duodenum
- +443 ;;^UTILITY(U,$J,358.3,1180,1,4,0)
- +444 ;;=4^C7A.010
- +445 ;;^UTILITY(U,$J,358.3,1180,2)
- +446 ;;=^5001359
- +447 ;;^UTILITY(U,$J,358.3,1181,0)
- +448 ;;=C7A.011^^10^77^44
- +449 ;;^UTILITY(U,$J,358.3,1181,1,0)
- +450 ;;=^358.31IA^4^2
- +451 ;;^UTILITY(U,$J,358.3,1181,1,3,0)
- +452 ;;=3^Malignant carcinoid tumor of the jejunum
- +453 ;;^UTILITY(U,$J,358.3,1181,1,4,0)
- +454 ;;=4^C7A.011
- +455 ;;^UTILITY(U,$J,358.3,1181,2)
- +456 ;;=^5001360
- +457 ;;^UTILITY(U,$J,358.3,1182,0)
- +458 ;;=C7A.012^^10^77^43
- +459 ;;^UTILITY(U,$J,358.3,1182,1,0)
- +460 ;;=^358.31IA^4^2
- +461 ;;^UTILITY(U,$J,358.3,1182,1,3,0)
- +462 ;;=3^Malignant carcinoid tumor of the ileum
- +463 ;;^UTILITY(U,$J,358.3,1182,1,4,0)
- +464 ;;=4^C7A.012
- +465 ;;^UTILITY(U,$J,358.3,1182,2)
- +466 ;;=^5001361
- +467 ;;^UTILITY(U,$J,358.3,1183,0)
- +468 ;;=C93.30^^10^77^38
- +469 ;;^UTILITY(U,$J,358.3,1183,1,0)
- +470 ;;=^358.31IA^4^2
- +471 ;;^UTILITY(U,$J,358.3,1183,1,3,0)
- +472 ;;=3^Juvenile myelomonocytic leukemia,no remission
- +473 ;;^UTILITY(U,$J,358.3,1183,1,4,0)
- +474 ;;=4^C93.30
- +475 ;;^UTILITY(U,$J,358.3,1183,2)
- +476 ;;=^5001825
- +477 ;;^UTILITY(U,$J,358.3,1184,0)
- +478 ;;=C93.31^^10^77^37
- +479 ;;^UTILITY(U,$J,358.3,1184,1,0)
- +480 ;;=^358.31IA^4^2
- +481 ;;^UTILITY(U,$J,358.3,1184,1,3,0)
- +482 ;;=3^Juvenile myelomonocytic leukemia,in remission
- +483 ;;^UTILITY(U,$J,358.3,1184,1,4,0)
- +484 ;;=4^C93.31
- +485 ;;^UTILITY(U,$J,358.3,1184,2)
- +486 ;;=^5001826
- +487 ;;^UTILITY(U,$J,358.3,1185,0)
- +488 ;;=C93.32^^10^77^36
- +489 ;;^UTILITY(U,$J,358.3,1185,1,0)
- +490 ;;=^358.31IA^4^2
- +491 ;;^UTILITY(U,$J,358.3,1185,1,3,0)
- +492 ;;=3^Juvenile myelomonocytic leukemia,in relapse
- +493 ;;^UTILITY(U,$J,358.3,1185,1,4,0)
- +494 ;;=4^C93.32
- +495 ;;^UTILITY(U,$J,358.3,1185,2)
- +496 ;;=^5001827
- +497 ;;^UTILITY(U,$J,358.3,1186,0)
- +498 ;;=D48.0^^10^78^5
- +499 ;;^UTILITY(U,$J,358.3,1186,1,0)
- +500 ;;=^358.31IA^4^2
- +501 ;;^UTILITY(U,$J,358.3,1186,1,3,0)
- +502 ;;=3^Neoplasm of uncertain behavior of bone/artic cartl
- +503 ;;^UTILITY(U,$J,358.3,1186,1,4,0)
- +504 ;;=4^D48.0
- +505 ;;^UTILITY(U,$J,358.3,1186,2)
- +506 ;;=^81953
- +507 ;;^UTILITY(U,$J,358.3,1187,0)
- +508 ;;=D48.1^^10^78^6
- +509 ;;^UTILITY(U,$J,358.3,1187,1,0)
- +510 ;;=^358.31IA^4^2
- +511 ;;^UTILITY(U,$J,358.3,1187,1,3,0)
- +512 ;;=3^Neoplasm of uncertain behavior of connctv/soft tiss
- +513 ;;^UTILITY(U,$J,358.3,1187,1,4,0)
- +514 ;;=4^D48.1
- +515 ;;^UTILITY(U,$J,358.3,1187,2)
- +516 ;;=^267776
- +517 ;;^UTILITY(U,$J,358.3,1188,0)
- +518 ;;=D48.5^^10^78^10
- +519 ;;^UTILITY(U,$J,358.3,1188,1,0)
- +520 ;;=^358.31IA^4^2
- +521 ;;^UTILITY(U,$J,358.3,1188,1,3,0)
- +522 ;;=3^Neoplasm of uncertain behavior of skin
- +523 ;;^UTILITY(U,$J,358.3,1188,1,4,0)
- +524 ;;=4^D48.5
- +525 ;;^UTILITY(U,$J,358.3,1188,2)
- +526 ;;=^267777
- +527 ;;^UTILITY(U,$J,358.3,1189,0)
- +528 ;;=D48.61^^10^78^9
- +529 ;;^UTILITY(U,$J,358.3,1189,1,0)
- +530 ;;=^358.31IA^4^2
- +531 ;;^UTILITY(U,$J,358.3,1189,1,3,0)
- +532 ;;=3^Neoplasm of uncertain behavior of right breast
- +533 ;;^UTILITY(U,$J,358.3,1189,1,4,0)
- +534 ;;=4^D48.61
- +535 ;;^UTILITY(U,$J,358.3,1189,2)
- +536 ;;=^5002267
- +537 ;;^UTILITY(U,$J,358.3,1190,0)
- +538 ;;=D48.62^^10^78^7
- +539 ;;^UTILITY(U,$J,358.3,1190,1,0)
- +540 ;;=^358.31IA^4^2
- +541 ;;^UTILITY(U,$J,358.3,1190,1,3,0)
- +542 ;;=3^Neoplasm of uncertain behavior of left breast
- +543 ;;^UTILITY(U,$J,358.3,1190,1,4,0)
- +544 ;;=4^D48.62
- +545 ;;^UTILITY(U,$J,358.3,1190,2)
- +546 ;;=^5002268
- +547 ;;^UTILITY(U,$J,358.3,1191,0)
- +548 ;;=D46.0^^10^78^18
- +549 ;;^UTILITY(U,$J,358.3,1191,1,0)
- +550 ;;=^358.31IA^4^2
- +551 ;;^UTILITY(U,$J,358.3,1191,1,3,0)
- +552 ;;=3^Refractory anemia without ring sideroblasts, so stated
- +553 ;;^UTILITY(U,$J,358.3,1191,1,4,0)
- +554 ;;=4^D46.0
- +555 ;;^UTILITY(U,$J,358.3,1191,2)
- +556 ;;=^5002245
- +557 ;;^UTILITY(U,$J,358.3,1192,0)
- +558 ;;=D46.1^^10^78^17
- +559 ;;^UTILITY(U,$J,358.3,1192,1,0)
- +560 ;;=^358.31IA^4^2
- +561 ;;^UTILITY(U,$J,358.3,1192,1,3,0)
- +562 ;;=3^Refractory anemia with ring sideroblasts
- +563 ;;^UTILITY(U,$J,358.3,1192,1,4,0)
- +564 ;;=4^D46.1
- +565 ;;^UTILITY(U,$J,358.3,1192,2)
- +566 ;;=^5002246
- +567 ;;^UTILITY(U,$J,358.3,1193,0)
- +568 ;;=D46.20^^10^78^14
- +569 ;;^UTILITY(U,$J,358.3,1193,1,0)
- +570 ;;=^358.31IA^4^2
- +571 ;;^UTILITY(U,$J,358.3,1193,1,3,0)
- +572 ;;=3^Refractory anemia with excess of blasts, unspecified
- +573 ;;^UTILITY(U,$J,358.3,1193,1,4,0)
- +574 ;;=4^D46.20
- +575 ;;^UTILITY(U,$J,358.3,1193,2)
- +576 ;;=^5002247
- +577 ;;^UTILITY(U,$J,358.3,1194,0)
- +578 ;;=D46.21^^10^78^15
- +579 ;;^UTILITY(U,$J,358.3,1194,1,0)
- +580 ;;=^358.31IA^4^2
- +581 ;;^UTILITY(U,$J,358.3,1194,1,3,0)
- +582 ;;=3^Refractory anemia with excess of blasts 1
- +583 ;;^UTILITY(U,$J,358.3,1194,1,4,0)
- +584 ;;=4^D46.21
- +585 ;;^UTILITY(U,$J,358.3,1194,2)
- +586 ;;=^5002248
- +587 ;;^UTILITY(U,$J,358.3,1195,0)
- +588 ;;=D46.A^^10^78^19
- +589 ;;^UTILITY(U,$J,358.3,1195,1,0)
- +590 ;;=^358.31IA^4^2
- +591 ;;^UTILITY(U,$J,358.3,1195,1,3,0)
- +592 ;;=3^Refractory cytopenia with multilineage dysplasia
- +593 ;;^UTILITY(U,$J,358.3,1195,1,4,0)
- +594 ;;=4^D46.A
- +595 ;;^UTILITY(U,$J,358.3,1195,2)
- +596 ;;=^5002251
- +597 ;;^UTILITY(U,$J,358.3,1196,0)
- +598 ;;=D46.B^^10^78^13
- +599 ;;^UTILITY(U,$J,358.3,1196,1,0)
- +600 ;;=^358.31IA^4^2
- +601 ;;^UTILITY(U,$J,358.3,1196,1,3,0)
- +602 ;;=3^Refract cytopenia w multilin dysplasia and ring sideroblasts
- +603 ;;^UTILITY(U,$J,358.3,1196,1,4,0)
- +604 ;;=4^D46.B
- +605 ;;^UTILITY(U,$J,358.3,1196,2)
- +606 ;;=^5002252
- +607 ;;^UTILITY(U,$J,358.3,1197,0)
- +608 ;;=D46.22^^10^78^16
- +609 ;;^UTILITY(U,$J,358.3,1197,1,0)
- +610 ;;=^358.31IA^4^2
- +611 ;;^UTILITY(U,$J,358.3,1197,1,3,0)
- +612 ;;=3^Refractory anemia with excess of blasts 2
- +613 ;;^UTILITY(U,$J,358.3,1197,1,4,0)
- +614 ;;=4^D46.22
- +615 ;;^UTILITY(U,$J,358.3,1197,2)
- +616 ;;=^5002249
- +617 ;;^UTILITY(U,$J,358.3,1198,0)
- +618 ;;=D46.C^^10^78^3
- +619 ;;^UTILITY(U,$J,358.3,1198,1,0)
- +620 ;;=^358.31IA^4^2
- +621 ;;^UTILITY(U,$J,358.3,1198,1,3,0)
- +622 ;;=3^Myelodysplastic syndrome w isolated del(5q) chromsoml abnlt
- +623 ;;^UTILITY(U,$J,358.3,1198,1,4,0)
- +624 ;;=4^D46.C
- +625 ;;^UTILITY(U,$J,358.3,1198,2)
- +626 ;;=^5002253
- +627 ;;^UTILITY(U,$J,358.3,1199,0)
- +628 ;;=D46.9^^10^78^4
- +629 ;;^UTILITY(U,$J,358.3,1199,1,0)
- +630 ;;=^358.31IA^4^2
- +631 ;;^UTILITY(U,$J,358.3,1199,1,3,0)
- +632 ;;=3^Myelodysplastic syndrome, unspecified
- +633 ;;^UTILITY(U,$J,358.3,1199,1,4,0)
- +634 ;;=4^D46.9
- +635 ;;^UTILITY(U,$J,358.3,1199,2)
- +636 ;;=^334031
- +637 ;;^UTILITY(U,$J,358.3,1200,0)
- +638 ;;=D47.1^^10^78^1
- +639 ;;^UTILITY(U,$J,358.3,1200,1,0)
- +640 ;;=^358.31IA^4^2
- +641 ;;^UTILITY(U,$J,358.3,1200,1,3,0)
- +642 ;;=3^Chronic myeloproliferative disease
- +643 ;;^UTILITY(U,$J,358.3,1200,1,4,0)
- +644 ;;=4^D47.1
- +645 ;;^UTILITY(U,$J,358.3,1200,2)
- +646 ;;=^5002256
- +647 ;;^UTILITY(U,$J,358.3,1201,0)
- +648 ;;=D47.Z1^^10^78^12
- +649 ;;^UTILITY(U,$J,358.3,1201,1,0)
- +650 ;;=^358.31IA^4^2
- +651 ;;^UTILITY(U,$J,358.3,1201,1,3,0)
- +652 ;;=3^Post-transplant lymphoproliferative disorder (PTLD)
- +653 ;;^UTILITY(U,$J,358.3,1201,1,4,0)
- +654 ;;=4^D47.Z1
- +655 ;;^UTILITY(U,$J,358.3,1201,2)
- +656 ;;=^5002261
- +657 ;;^UTILITY(U,$J,358.3,1202,0)
- +658 ;;=D48.7^^10^78^8
- +659 ;;^UTILITY(U,$J,358.3,1202,1,0)
- +660 ;;=^358.31IA^4^2
- +661 ;;^UTILITY(U,$J,358.3,1202,1,3,0)
- +662 ;;=3^Neoplasm of uncertain behavior of other specified sites
- +663 ;;^UTILITY(U,$J,358.3,1202,1,4,0)
- +664 ;;=4^D48.7
- +665 ;;^UTILITY(U,$J,358.3,1202,2)
- +666 ;;=^267779
- +667 ;;^UTILITY(U,$J,358.3,1203,0)
- +668 ;;=D48.9^^10^78^11